Technical Analysis for ITCI - Intra-Cellular Therapies Inc.

Grade Last Price % Change Price Change
grade F 12.29 -1.76% -0.22
ITCI closed down 1.76 percent on Monday, May 20, 2019, on 85 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ITCI trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
50 DMA Resistance Bearish -1.76%
20 DMA Resistance Bearish -1.21%
50 DMA Resistance Bearish -1.21%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.21%
NR7 Range Contraction -0.57%
Inside Day Range Contraction -0.57%
MACD Bearish Centerline Cross Bearish -1.92%
Lower Bollinger Band Walk Weakness -1.92%
Lower Bollinger Band Touch Weakness -1.92%

Older signals for ITCI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS). Its lead product candidate includes ITI-007, which is in various clinical trials for the treatment of exacerbated and residual schizophrenia; bipolar disorders; sleep deficits associated with neurologic and psychiatric disorders; behavioral disturbances associated with dementia, including Alzheimer's disease; sleep maintenance insomnia; major depressive disorders; and autism spectrum disorders, PTSD, and IED. The company also develops ITI-002 phosphodiesterase (PDE) 1 inhibitors, including ITI-214 program that is in Phase-I clinical trial for the treatment of cognitive dysfunction in schizophrenia, as well as in pre-clinical stage for the treatment of Parkinson's disease, cognitive impairment in Alzheimer's disease, and attention deficit/hyperactivity disorders; and ITI-002 internal program that is pre-clinical stage for cardiovascular and other diseases. In addition, it develops early stage drug development programs comprising ITI-012 casein kinase 1 inhibitors and ITI-009 gamma secretase activating protein inhibitors for Alzheimer's disease. Further, the company develops PDE2 and PDE9 targets for treating neurodegeneration and bioenergetic failure in various CNS diseases. It has a license and collaboration agreement with Takeda Pharmaceutical Company Limited to research, develop, and commercialize the company's proprietary compound ITI-214 and other selected compounds that selectively inhibit PDE1 for use in the prevention and treatment of human diseases. The company is headquartered in New York, New York.
Medicine Biopharmaceutical Disorders Neuroscience Alzheimer's Disease Schizophrenia Parkinson's Disease Drug Development Psychiatry Psychiatric Diagnosis Dementia Treatment Of Parkinson's Disease Aging Associated Diseases Human Diseases Cognitive Disorders Major Depressive Disorders Bipolar Disorders Cardiovascular And Other Diseases Cognitive Dysfunction Cognitive Impairment Learning Disabilities
Is ITCI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 23.64
52 Week Low 10.21
Average Volume 319,571
200-Day Moving Average 15.5986
50-Day Moving Average 12.8416
20-Day Moving Average 13.109
10-Day Moving Average 12.696
Average True Range 0.7893
ADX 14.37
+DI 17.1003
-DI 20.9949
Chandelier Exit (Long, 3 ATRs ) 12.0121
Chandelier Exit (Short, 3 ATRs ) 13.9029
Upper Bollinger Band 14.3941
Lower Bollinger Band 11.8239
Percent B (%b) 0.18
BandWidth 19.606377
MACD Line -0.1593
MACD Signal Line -0.023
MACD Histogram -0.1363
Fundamentals Value
Market Cap 533.68 Million
Num Shares 43.4 Million
EPS -2.36
Price-to-Earnings (P/E) Ratio -5.21
Price-to-Sales 2144.19
Price-to-Book 1.97
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.92
Resistance 3 (R3) 12.90 12.66 12.82
Resistance 2 (R2) 12.66 12.50 12.68 12.78
Resistance 1 (R1) 12.48 12.40 12.36 12.50 12.74
Pivot Point 12.24 12.24 12.19 12.26 12.24
Support 1 (S1) 12.06 12.08 11.94 12.08 11.84
Support 2 (S2) 11.82 11.98 11.84 11.80
Support 3 (S3) 11.64 11.82 11.77
Support 4 (S4) 11.66